UICC EML Review 2014
|
|
- Rosemary Brown
- 5 years ago
- Views:
Transcription
1 UICC EML Review 2014 Granulocyte Stimulating Agents (G- CSF) Supplemental Document Many antineoplastic agents are cytotoxic to the bone marrow and prevent the development of granulocytes necessary to fight infection. Neutropenia is defined as an Absolute Neutrophil Count of less than 500 cells per microliter. When a patient is neutropenic, a fever may be the only sign of infection, which may rapidly progress to sepsis and death if empiric antibiotics are not given. Febrile neutropenia is a medical emergency and carries a substantial increase in morbidity, mortality, hospitalizations, and cost of care. This is a serious complication and avoidance of febrile neutropenia is a meaningful goal of holistic care of the patient with cancer. In the absence of essential medicines to stimulate the proliferation of granulocytes to fight infection, physicians must reduce the dose or delay the timing of chemotherapy delivery. Discovered in the 1980s, Granulocyte- Colony Stimulating Factor (G- CSF) is a glycoprotein that stimulates the bone marrow to produce granulocytes, and promotes their survival, proliferation, and differentiation. When initiated early in the first cycle of chemotherapy and continued through all cycles of a chemotherapy regimen, CSFs substantially reduce the risk of Febrile Neutropenia. This usage of G- CSF during the first and all subsequent cycles of chemotherapy is called primary prophylaxis. This is an important clinical outcome, regardless of impact on other factors. It has also been shown to reduce the risk of infection- related and early all- cause mortality, while at the same time reducing the need for delays or dose reduction in chemotherapy treatment. 1 Stratifying a Patient s Risk for FN G- CSFs are expensive agents, but when used in the correct clinical setting can reduce the overall cost of a patient s care by directly reducing the risk of febrile neutropenia. Thus, use of G- CSFs is justified only in patients deemed to be high risk for developing febrile neutropenia. A patient s risk is based both on risks inherent to the myelosuppression induced by specific chemotherapy regimens and on the individual s health factors. The following clinical factors put a patient at a higher risk of developing severe complications from prolonged neutropenia: 2 Patient age greater than 65 years Poor performance status Prior episodes of FN Extensive prior treatment including large radiation ports Administration of combined chemotherapy Cytopenias due to bone marrow involvement by tumor Poor nutritional status The presence of open wounds or active infections More advanced cancer Other serious comorbidities The prevalence of some of these factors may be increased in low- resource settings and the consequences of febrile neutropenia may be even more striking.
2 When to Use G- CSF If a patient s individual risk of Febrile Neutropenia is estimated to be 20% or greater, CSFs should be used for primary prophylaxis if no other equally effective regimen is possible that would not require the use of CSFs. 3 If a patient has had a neutropenic complication (febrile neutropenia or documented infection during neutropenic episode) from a prior cycle of chemotherapy, he or she should receive secondary prophylaxis beginning during the next cycle. For low- risk patients, those with a less than 20% risk of developing febrile neutropenia, routine use of CSF s is not considered cost- effective according to a commentary by Smith & Hillner assessing cost- effectiveness literature. 4 Table 1. Utilization of G- CSF in Pediatric Oncology Status Disease Protocol Institution/Group Reference Mandated Ewing sarcoma AEWS ) Precluded Standard risk ALL ) Children s Oncology Group DFCI* Childhood ALL Consortium Eur J Cancer 2000; 36: J Clin Oncol 2012; 30: J Clin Oncol 2013; 31: Allowed (in defined circumstance)** Osteosarcoma EURAMOS ) Combined European- North American Study Cancer Treat Res 2009; 152: *DFCI = Dana Farber Cancer Institute **Only after an episode of fever and neutropenia Choosing Regimens relative to risk of causing neutropenia and fever Treatment with Curative Intent In certain circumstances dose intensity and schedule impact on long- term survival. There remains a significant amount of variation in the use of G- CSF in cancer treatment among various patient cohorts, as is discussed elsewhere. 5,6,7 However, when there is clear evidence that a regimen with sufficient myelosuppression requires primary or secondary prophylaxis with G- CSF, then this would be an appropriate choice of therapy. 8 The incremental benefit of dose intense regimen versus a less intense regimen not requiring G- CSF will factor into this decision.
3 Treatment with Palliative Intent In most cases, patients treated with palliative intent should not be treated with intensive regimens that require G- CSF. The primary reason for this is that for most patients with most diseases in this situation, it has not been demonstrated that intensive therapies improve overall survival, nor have dose- dense therapies been associated with gains in quality of life. With breast cancer as an example, ASCO recommends sequential single- agent therapy rather than more intensive multi- agent therapy for patients with metastatic disease. 9 Use of G- CSF in treatment of acute leukemia and myelodysplastic syndrome The considerations are different for the usage of G- CSFs for patients with Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and Myelodysplastic Syndrome (MDS). In patients with AML, the priming of leukemia cells with G- CSF is not recommended. CSF use is recommended, however, in patients with AML after the completion of consolidation chemotherapy and has been shown to decrease the incidence of infection and eliminate the likelihood of hospitalization in some patients. CSFs should be used judiciously or not at all in patients with refractory or relapsed myeloid leukemia. The expected benefit of only a few days of shortened neutropenia does not outweigh the cost; CSFs may make it difficult to distinguish between the stimulatory effect of CSFs or drug resistance as the cause of persistent leukemia. CSFs have been shown to increase the absolute neutrophil count in neutropenic patients with MDS. While there is insufficient data that long- term, continuous use of CSFs is beneficial, intermittent administration of CSFs may help in a subset of patients with MDS with severe neutropenia and recurrent infections. There is a potential risk for secondary myeloid leukemia or myelodysplastic syndrome (AML/MDS) associated with CSFs. When given to patients with ALL during the first few days of either the initial induction or of the first post- remission course of chemotherapy, CSFs may shorten the duration of neutropenia. On the other hand, in children with ALL, who would otherwise have an excellent prognosis, the benefits of CSFs may not outweigh the risks of AML/MDS. How to Use In general, for primary prophylaxis, G- CSF should be given 24 to 72 hours after the administration of myelotoxic chemotherapy. A dose of 5 mg/kg/day should be continued until a target absolute neutrophil count of at least 2 or 3 x 10 9 cells/l are reached. G- CSF has a short half- life and requires daily subcutaneous injections. A polyethylene glycol conjugated (PEGylated) G- CSF was developed, which only needs to be injected once per chemotherapy cycle. A large, WHO- endorsed study in 2013 established the International Standard for PEGylated G- CSF with an assigned in vitro bioactivity of 10,000 IU per ampoule. PEGylated G- CSF 6 mg should be given once, 24 hours after completion of chemotherapy. Filgrastim vs Pegfilgrastim Several studies have shown the comparability in effectiveness of filgrastim (daily subcutaneous injection) and pegfilrastim (once per cycle subcutaneous injection). The two drugs have similar safety profiles and have been shown to provide similar neutrophil support. 10 Several studies have demonstrated the comparability of patient outcomes on the two different forms of G- CSF. 11,12,13 A meta- analysis in 2007 analyzing outcomes among patients with different types of cancer (including different chemotherapy regimens) concluded that pegfilgrastim produced moderately better outcomes, 14 however in general,
4 the choice between filgrastim and pegfilgrastim largely concerns individual clinical preference about ease of administration and the difference in cost, with pegfilgrastim being much more expensive. Additionally, there are biosimilars available for filgrastim, allowing for a lower price with comparable clinical efficacy. Several recent studies have determined pegfilgrastim to be more cost- effective or more cost- saving as compared to filgrastim despite the drug being more expensive overall. 15,16,17 One recent analysis of patients on several regimens in Europe concluded that a filgrastim biosimilar, Zarzio was more cost- effective than filgrastim and pegfilgrastim. 18 However, guidelines generally remain accepting of both options depending on patient circumstances and cost considerations within the health system concerned in the analysis. 19 Consideration for Afebrile Neutropenia or as Treatment for Febrile Neutropenia G- CSF has also shown no benefit in patients with afebrile neutropenia or as a treatment for most patients who have already developed febrile neutropenia. However, if a patient has a fever, neutropenia, and is at high- risk for infection- associated complications, CSFs should be considered. These high- risk features include the following: Expected prolonged (>10 days) and profound (<0.1 x 10 9 /L) neutropenia Age greater than 65 years Uncontrolled primary disease Pneumonia Hypotension and multiorgan dysfunction (sepsis syndrome) Invasive fungal infection Being hospitalized at the time of development of fever Use in Autologous Progenitor Cell Transplantation (not applicable in resource constrained settings CSFs help mobilize peripheral- blood progenitor cells and the administration of CSFs as adjuncts to autologous progenitor- cell transplantation has become the standard of care. This has been shown to reduce hospital stays and overall medical costs. On the other hand, CSFs should not be used after allogeneic transplant because in this setting they have been shown to increase Graft versus Host Disease, and to decrease overall survival. Intermediate Risk NCCN: Individualized consideration of CSF use based on physician- patient discussion of the risk- benefit ratio of the likelihood of developing FN, the potential consequences of a neutropenic event and the implications of reduced chemotherapy dose delivery.
5 1 Kuderer NM, Lyman GH: Personalized medicine and cancer supportive care: Appropriate use of colony- stimulating factor support of chemotherapy. J Natl Cancer Inst 103: , Smith TJ, Khatcheressian J, Lyman GH, et al Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence- Based Clinical Practice Guideline. J Clin Oncol 24(19): Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology. J Clin Oncol 30(14): , Smith TJ & Hillner BE. A Way Forward on the Medically Appropriate Use of White Cell Growth Factors. J Clin Oncol 30(14): Smith TJ & Hillner BE. A Way Forward on the Medically Appropriate Use of White Cell Growth Factors. J Clin Oncol 30(14): Swanson G, Bergstrom K, Stump E, et al: Growth factor usage patterns and outcomes in the community setting: Collection through a practice- based computerized clinical information system. J Clin Oncol 18: , Potosky AL, Malin JL, Kim B, et al: Use of colony stimulating factors with chemotherapy: Op- portunities for cost savings and improved out- comes. J Natl Cancer Inst 103: , Smith TJ, Khatcheressian J, Lyman GH, et al Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence- Based Clinical Practice Guideline. J Clin Oncol 24(19): Schnipper LE, Lyman GH, Blayney DW, et al. American Society of Clinical Oncology 2013 Top Five List in Oncology. J Clin Oncol 31(34): , Holmes FA, Jones SE, O Shaughnessy J, et al. Comparable efficacy and safety profiles of once- per- cycle pegfilgrastim and daily injection filgrastim in chemotherapy- induced neutropenia: a multicenter dose- finding study in women with breast cancer. Annals of Oncology 13(6): , Cesaro S, Nesi F, Tridello G, et al. A Randomized, Non- Inferiority Study Comparing Efficacy and Safety of a Single Dose of Pegfilgrastim versus Daily Filgrastim in Pediatric Patients after Autologous Peripheral Blood Stem Cell Transplant. PLOS One January 7, Vose JM, Crump M, Lazarus H. Randomized, Multicenter, Open- Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma. J Clin Oncol 21(3): Homes FA, O Shaughnessy JA, Vukelja S. Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High- Risk Stage II or Stage III/IV Breast Cancer. J Clin Oncol 20(3) , Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta- analysis of randomized controlled trials. Current Medical Research and Opinion 23(9): , Lyman G, Lalla A, Barron R, and Dubois RW. Cost- effectiveness of pegfilgrastim versus 6- day filgrastim primary prophylaxis in patients with non- Hodgkin's lymphoma receiving CHOP- 21 in United States. Curr Med Res Opin 25(2):401-11, Lyman GH, Lalla A, Barron RL, Dubois RW. Cost- effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early- stage breast cancer receiving chemotherapy in the united states. Clinical Therapeutics 31(5): , Danova M, Chiroli S, Rosti G, and Doan QV. Cost- effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori 95: , Aapro M, Cornes P, and Abraham I. Comparative cost- efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy- induced febrile neutropenia. J Oncol Pharm Pract 18(2): , Aapro MS, Bohlius J, Cameron DA update of EORTC guidelines for the use of granulocyte- colony stimulating factor to reduce the incidence of chemotherapy- induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur Journal of Cancer 47(1):8-32, 2011
Corporate Medical Policy
White Blood Cell Growth Factors Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: white_blood_cell_growth_factors 9/2016 4/2017 4/2018 6/2017 Description of
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More informationReference No: SG 23/13
Title: Author(s) Ownership: Approval by: Guidelines for the use of granulocyte colony stimulating factor (GSCF) in adult oncology & malignant haematology patients Paula Scullin, Consultant Medical Oncologist,
More informationGUIDELINES FOR THE USE OF G-CSF & PEGFILGRASTIM (NEULASTA)
GUIDELINES FOR THE USE OF G-CSF & PEGFILGRASTIM (NEULASTA) Document Reference: N/A Version: V1.1 Dr Andrew Sykes Document Document June So Owner: Chair Drugs & Author: Director of Pharmacy Therapeutics
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More information2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationGuidelines for the use of G-CSF in the Department of Oncology
Guidelines for the use of G-CSF in the Department of Oncology Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationReady to answer the questions?
파워포인트문서의제목 Reference 1. IDSA GUIDELINES. Clinical Practice Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Disease Society of America.
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 6 Last Review Date: September 15, 2017 Granix Description Granix (tbo-filgrastim)
More informationCritical Reviews in Oncology/Hematology 78 (2011) Jean Klastersky, Ahmad Awada
Critical Reviews in Oncology/Hematology 78 (2011) 17 23 Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have
More informationFor peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation
Last Review: 4/2010 NON-FORMULARY Clinical Guideline Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF), Neumega (oprelvekin; rh-il-11), Leukine (sargramostim; GM-CSF) Indications Neupogen
More informationNeupogen (Filgrastim)/Neulasta (Pegfilgrastim)
Policy Number Reimbursement Policy NEU12182013RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 12/18/2013 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This
More informationClinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea
Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast
More informationMonitor G-CSF Study Treatment patterns and outcomes in the prophylaxis of chemotherapy induced neutropenia with biosimilar filgrastim (Zarzio )
Monitor G-CSF Study Treatment patterns and outcomes in the prophylaxis of chemotherapy induced neutropenia with biosimilar filgrastim (Zarzio ) Heinz Ludwig Wilhelminen Cancer Research Institute c/o I
More informationCANCER RELATED INFECTION AND USE OF COLONY STIMULATING FACTORS
CANCER RELATED INFECTION AND USE OF COLONY STIMULATING FACTORS Suphat Subongkot, Pharm.D, BCPS, BCOP Clinical Pharmacy, Khon Kaen University, Thailand Learning Objectives Summarize national guidelines
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
More informationCircle Yes or No Y N. (Note: requests without this information will not be accepted.) [If no, then no further questions.]
04/25/2016 Prior Authorization AETA BETTER HEALTH OF LA MEDICAID Colony Stimulating Factors (LA88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationGuideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology
(G-CSF) for Adults in Oncology and Haematology For Use in: By: Oncology and Haematology Inpatients and Outpatients Oncologists and Haematologists For: Division responsible for document: Key words: Name
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
More informationManagement of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value
e1 Management of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value Michaela A. Dinan, PhD a,b ; Bradford R. Hirsch, MD, MBA a,b ; and Gary H. Lyman, MD, MPH c,d Abstract Treatment-associated
More informationMay 22, NCCN Clinical Practice Guidelines Panel: Myeloid Growth Factors
Charles Bowers, MD Clinical Research US Medical, Neupogen/Neulasta Amgen, Inc. One Amgen Center Drive Thousand Oaks, CA 91321-1799 (805) 447-0757 Cbower01@amgen.com May 22, 2017 NCCN Clinical Practice
More informationCircle Yes or Y N. [Note: requests without this information will not be accepted.] [If no, then no further questions.
10/01/2016 Prior Authorization Aetna Better Health of West Virginia COLO STIMULATIG FACTORS (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.08 Subject: Leukine Page: 1 of 6 Last Review Date: March 13, 2014 Leukine Description Leukine (sargramostim)
More informationOriginal Article. Yuichiro Kume, Yasuaki Nakajima, Takuya Okada, Akihiro Hoshino, Yutaka Tokairin, Kenro Kawada and Yusuke Kinugasa
19 2018; 65: 19-25 Y. Kume et al. Original Article A comparative analysis between pegfilgrastim and lenograstim administered to patients receiving cytotoxic chemotherapy for squamous cell carcinoma of
More informationCanadian supportive care recommendations for the management of neutropenia in patients with cancer
PRACTICE GUIDELINE SERIES Canadian supportive care recommendations for the management of neutropenia in patients with cancer C.T. Kouroukis MD MSc,* S. Chia MD, S. Verma MD, D. Robson MD, C. Desbiens MD,
More informationColony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous)
Colony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous) Document Number: MODA-0375 Last Review Date: 08/06/2018 Date of Origin: 08/06/2018 Dates Reviewed: 08/2018 I. Length of
More informationEffect of Outpatient Treatment of Febrile Neutropenia on the Risk Threshold for the Use of CSF in Patients with Cancer Treated with Chemotherapy
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152005 ISPOR814752Original ArticleOutpatient Treatment of Febrile NeutropeniaCosler et al. Volume 8 Number 1 2005 VALUE IN HEALTH Effect of Outpatient
More informationIOM Workshop: Achieving Value in Cancer Care: ASCO s Top 5 and Beyond Lowell E. Schnipper, M.D.
IOM Workshop: Achieving Value in Cancer Care: ASCO s Top 5 and Beyond Lowell E. Schnipper, M.D. Expenditures Cancer Care: 2010 Initial dx, continuing care, last phase Costs of Cancer Care: breast, colorectal,
More informationLCD for Sargramostim (GM-CSF, Leukine ) (L29275)
LCD for Sargramostim (GM-CSF, Leukine ) (L29275) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD ID Number L29275 LCD Information
More informationColony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous)
Colony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous) Document Number: IC 0245 Last Review Date: 5/1/2018 Date of Origin: 03/31/2015 Dates Reviewed: 03/2015, 05/2015, 08/2015,
More informationClinical Policy: Pegfilgrastim (Neulasta) Reference Number: CP.CPA.127 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Neulasta) Reference Number: CP.CPA.127 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationWHITE BLOOD CELL COLONY STIMULATING FACTORS
UnitedHealthcare Community Plan Medical Benefit Drug Policy WHITE BLOOD CELL COLONY STIMULATING FACTORS Policy Number: CS2018D0061C Effective Date: June 1, 2018 Table of Contents Page INSTRUCTIONS FOR
More informationHematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF).
Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte colony-stimulating factor(g-csf). Granulocyte-macrophage colonystimulating factor (G-CSF). Interleukin-11
More informationProphylaxis of febrile neutropenia :experiences with adjuvant TAC
Prophylaxis of febrile neutropenia :experiences with adjuvant TAC 30 th Apr, 2016 Jihyoun Lee Breast center, Department of Surgery Soonchunhyang University Hospital Chemotherapy and the risk of febrile
More informationClass Update with New Drug Evaluation: Colony Stimulating Factors (CSF)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSystematic Reviews in Hematological Malignancies
Systematic Reviews in Hematological Malignancies Pia Raanani, MD Davidoff Cancer Center Rabin Medical Center, Israel 1 2 Disorder CHMG Systematic review* Title Protocol Full Review Myelodysplastic syndrome
More informationNeutropenia is defined as a neutrophil count of less than 500 cells per mm3,
CHEMOTHERAPY-INDUCED NEUTROPENIA: IMPORTANT NEW DATA TO GUIDE NURSING ASSESSMENT AND MANAGEMENT Christopher R. Friese, RN, PhD, AOCN* ABSTRACT Chemotherapy-induced neutropenia is the most serious hematologic
More informationWHITE BLOOD CELL COLONY STIMULATING FACTORS
ell UnitedHealthcare Oxford Clinical Policy WHITE BLOOD CELL COLONY STIMULATING FACTORS Policy Number: PHARMACY 296.2 T2 Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS
More informationShannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008
Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Study Title: Observational Study to Determine the Effect of an Emergency Department Adult Oncology Stat Antibiotic Protocol on Clinical Outcomes
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationCo-morbidities in Elderly Breast and Lung Cancer Patients who receive Chemotherapy of NCCN defined Intermediate Risk of Febrile Neutropenia
Co-morbidities in Elderly Breast and Lung Cancer Patients who receive Chemotherapy of NCCN defined Intermediate Risk of Febrile Neutropenia Authors: John H. Page, Shuling Li, Julia Molony, Romina Sosa,
More informationPharmacy Medical Necessity Guidelines: Neulasta (pegfilgrastim)
Pharmacy Medical Necessity Guidelines: Effective: October 1, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationWHITE BLOOD CELL COLONY STIMULATING FACTORS
UnitedHealthcare Commercial Medical Benefit Drug Policy WHITE BLOOD CELL COLONY STIMULATING FACTORS Policy Number: PHA043 Effective Date: February 1, 2019 Table of Contents Page INSTRUCTIONS FOR USE...
More informationGuidelines in the Management of Febrile Neutropenia for Clinical Practice
REFERENCES 1. Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA. Cancer treatment cost in the United States: has the burden shifted over time? Cancer. 2010;116(14):3477-3484.
More informationClinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295
Clinical Policy: (Leukine) Reference Number: CP.PHAR.295 Effective Date: 12/16 Last Review Date: 10/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationOriginal article. The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy
Annals ofoncology 8: 7-24, 997. O 997 Kluwer Academic Publishers. Printed in the Netherlands. Original article The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy J.
More informationContents Please refer to Medical Policy I-4, Hemophilia Treatment for additional information.
August 2018 In This Issue Coverage Guidelines Updated for Hemophilia Treatment... 2 Coverage Criteria Revised for Nusinersen (Spinraza)... 6 Coverage Guidelines Developed for Vestronidase Alpha (Mepsevii)...
More informationPreventing Neutropenic Complications
Preventing Neutropenic Complications Michael Rader, MD Clinical Assistant Professor of Medicine, Columbia University College of Physicians and Surgeons Director, Union State Bank Cancer Center at Nyack
More informationColony-stimulating factors
Colony stimulating factors page 1 APC/DTC Briefing Document Colony-stimulating factors Contents Conclusions from clinical evidence 1 Background 2 Clinical guidelines 2 Licensed indications 3 Clinical evidence
More informationTECHNOLOGY OVERVIEW: PHARMACEUTICALS
TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 9.0 DECEMBER 1997 THE USE OF G-CSF IN THE PREVENTION OF FEBRILE NEUTROPENIA based primarily on the Technical Report : The Cost-Effectiveness of G-CSF for Prophylaxis
More informationRole of Pharmacist in Supportive care cancer
Role of Pharmacist in Supportive care cancer Manit Sae-teaw B.Pharm, BCOP, BCP Grad. Dip. In Pharmacotherapy Faculty of Pharmaceutical Science Ubon Ratchathani University 1 Outline Cancer facts Supportive
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationManufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
Brand Name: Mylotarg Generic Name: gentuzumab ozogamicin Manufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. Drug Class: CD33-directed antibody-drug conjugate Uses: Labeled Uses: Newly-diagnosed
More informationFebrile neutropenia. Febrile neutropenia. Febrile neutropenia. Febrile neutropenia 1/30/2019. Infection in patients with cancer
Manit Sae-teaw B.Pharm, BCP, BCOP Glad dip in pharmacotherapy Faculty of pharmaceutical sciences Ubon Ratchathani University Fever Oral temperature measurement of 38.3 C (101.0 F) single 38.0 C (100.4
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationVolume 25, Issue 3 Summer 2015 ISSN: X (print), (online)
Volume 25, Issue 3 Summer 2015 ISSN: 1181-912X (print), 2368-8076 (online) INTERNATIONAL PERSPECTIVE Management of chemotherapy-induced febrile neutropenia among adult oncology patients: A review by Audai
More informationHematopoietic Growth Factors* Defining the Appropriate Clinical Role in Multimodality Cancer Therapy
Hematopoietic Growth Factors* Defining the Appropriate Clinical Role in Multimodality Cancer Therapy George D. Demetri, MD Laboratory investigations have begun to elucidate the regulatory molecules that
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 16 December 2009 MOZOBIL 20 mg/ml, solution for injection Box containing 1 vial (CIP: 397 153-7) Applicant: GENZYME
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationOncologic Applications of Interleukin-2 (Aldesleukin) When Used as Monotherapy. Original Policy Date
MP 8.01.03 Oncologic Applications of Interleukin-2 (Aldesleukin) When Used as Monotherapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with
More informationSequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide
Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide Review Article [1] April 01, 1997 By Clifford A. Hudis, MD [2] The recognition of paclitaxel's (Taxol's) activity
More informationHEMATOPOIETIC CELL TRANSPLANTATION FOR SOLID TUMORS OF CHILDHOOD
CHILDHOOD Non-Discrimination Statement Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices drugs are dependent upon
More informationOncologist. The. Symptom Management and Supportive Care. Risk Models for Predicting Chemotherapy-Induced Neutropenia
The Oncologist Symptom Management and Supportive Care Risk Models for Predicting Chemotherapy-Induced Neutropenia GARY H. LYMAN, CHRISTOPHER H. LYMAN, OLAYEMI AGBOOLA, FOR THE ANC STUDY GROUP Health Services
More informationClinical Guidelines for Leukaemia and other Myeloid Disorders MDS
Clinical Guidelines for Leukaemia and other Myeloid Disorders MDS Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-106 2 Dr Helen Barker MDT Lead
More informationScottish Medicines Consortium
Scottish Medicines Consortium azacitidine 100mg powder for suspension for injection (Vidaza ) No. (589/09) Celgene Ltd 05 March 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationSpecific Cancer Diagnosis. Age Range France No 149 NR NHL Cancer NA Chemo COPADM
APPENDIX 11: RANDOMIZED CONTROLLED TRIALS OF ANY INTERVENTION FOR THE PREVENTION OF ORAL MUCOSITIS IN PEDIATRIC PATIENTS RECEIVING TREATMENT FOR CANCER OR UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 47 July 2011
Area Drug and Therapeutics Committee Prescribing Supplement No 47 In this issue Drugs reviewed by in May / June 2011 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationExamining the Clinical and Cost-Effectiveness in Managing Chemotherapy- Induced Severe Neutropenia
Examining the Clinical and Cost-Effectiveness in Managing Chemotherapy- Induced evere Neutropenia Faculty Christopher A. Fausel, PharmD, MHA, BCOP Adjunct fessor Indiana University chool of Medicine Clinical
More information# # % # & # # ( # # ) # +,../ % & ( ( 7 #..0.
! # # % # & # # ( # # ) # +,../ % 0 1 0 2 1 3 4 4 & 1 2 56( ( 7 #..0. 8 HEDS Discussion Paper 11-01 Disclaimer: This is a Discussion Paper produced and published by the Health Economics and Decision Science
More informationInvestigating Plinabulin for Prevention of Chemotherapy-Induced Neutropenia
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/project-oncology/origins-and-impacts-severe-neutropenia-newpharmacotherapy/9650/
More informationImportant new concerns or changes to the current ones will be included in updates of YESCARTA s RMP.
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for YESCARTA (axicabtagene ciloleucel) This is a summary of the risk management plan (RMP) for YESCARTA. The RMP details important
More informationCautionary Note Regarding Forward-Looking Statements
lndoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1
More informationUnderstanding the role of ex vivo T cell depletion
Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_ transplantation_for_primary_amyloidosis 2/2001 11/2018 11/2019 11/2018 Description
More informationTRANSPARENCY COMMITTEE. The legally binding text is the original French version OPINION. 21 June 2006
TRANSPARENCY COMMITTEE The legally binding text is the original French version OPINION 21 June 2006 Granocyte 13 (13.4 million IU/1 ml), powder and solvent in prefilled syringe for solution for injection
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 ANTILYMPHOCYTE GLOBULINS FRESENIUS 20 mg/ml, solution to dilute for infusion 10 glass bottle(s) of 5
More informationKelly Fust 1 Xiaoyan Li. Richard Barron 2 Milton C. Weinstein. Gary H. Lyman 8
PharmacoEconomics (2017) 35:425 438 DOI 10.1007/s40273-016-0474-0 ORIGINAL RESEARCH ARTICLE Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia
More informationTransition from active to palliative care EBMT, Geneva, Dr. med. Gayathri Nair Division of Hematology
Transition from active to palliative care EBMT, Geneva, 03.04.2012 Dr. med. Gayathri Nair Division of Hematology 3 cases of patients who underwent an allogeneic stem cell transplantation in curative intent
More informationGeneral Authorization Criteria for ALL Agents and Indications:
Neulasta (peg-filgrastim; G-CSF) Neupogen (filgrastim; G-CSF) Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF) General Authorization Criteria for ALL Agents and Indications: Prescribed
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationRelative dose intensity delivered to patients with early breast cancer: Canadian experience
M E D I C A L O N C O L O G Y Relative dose intensity delivered to patients with early breast cancer: Canadian experience S. Raza MD, S. Welch MD, and J. Younus MD ABSTRACT Adjuvant chemotherapy for early
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Tisagenlecleucel-T for previously treated B-cell acute lymphoblastic Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationFEBRILE NEUTROPENIA CURRENT GUIDELINES FOR CHILDREN Alia Zaidi, MD. St. Jude International Outreach Program
SIOP PODC Supportive Care Education (ICON 2016) Presentation Date: 23 rd January 2016 Recording Link at www.cure4kids.org: https://www.cure4kids.org/ums/home/conference_rooms/enter.php?room=p25oti35nt7
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationGuideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation
Guideline for the Management of Fever Neutropenia in Children with Cancer /or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationHematologic Malignancies 2013 Retrospective Study at Truman Medical Center
Hematologic Malignancies 2013 Retrospective Study at Truman Medical Center Kristen Strasser, MD & Abdulraheem Qasem, MD Introduction: Hematologic Malignancies includes malignant diseases of the bone marrow
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More information